Breast Cancer Academy

Elena Cecchettin, sorella di Giulia uccisa dall'ex fidanzato Filippo Turetta l'11 novembre 2023, ha continuato a fare rumore per Giulia e a gridare contro una cultura dove «nessun uomo è buono se non fa nulla per smantellare la società che li privilegia tanto». Il 12 maggio Elena sarà al Salone Internazionale del Libro di Torino con Alessandra Campani, socia fondatrice dell’associazione Nondasola, e Barbara Stefanelli, vicedirettrice vicaria del Corriere della Sera per incontrare le ragazze e i ragazzi. Qui potete inviarci le vostre domande per lei: ne discuteremo al Salone 27esimaora.corriere.it/24_aprile_25/f…

Very happy to see that our paper on @eBioMedicine is the Editor's pick from the April issue! B-cell immunity is finally gaining its spot in the onocoimmunology field. In this paper we show how it is associated with pCR and prognosis in TNBC ⬇️@prat_aleix @evomet_itn @fara_bm

On-line nuovi materiali! 📚Disponibili i materiali (PDF, video) del webinar di dicembre che ha presentato una selezione di lavori presentati all'ultimo San Antonio Breast Cancer Symposium. tinyurl.com/56phrzhd #breastcancer #SABCS23 #oncology

🔬Breaking barriers in #TNBC Unleashing the power of #ADCs 👉🏼 doi.org/10.1016/j.ctrv… Thanks to Arianna Dri and the extraordinary group of coauthors @arpino_grazia 
@BianchiniGP @curijoey 
@MicheleDelauren @delmastro_lucia @alessandrafab11 @ALEDIGNUS12 
@valeguarneri

L’analisi di un gene potrà rivelare il periodo ideale di trattamento per minimizzare i rischi e amplificare i benefici in ogni donna colpita da tumore al seno positivo per i recettori ormonali. Studio finanziato da @MinisteroSalute Leggi di più 👇 ospedalesanmartino.it/it/ricerca-sci… @AACR

WEBINAR LIVE Breast Cancer Academy: le novità da San Antonio 1,5 Crediti ECM | 18 dicembre 2023 ISCRIVITI ORA tinyurl.com/2h88jhfm #breastcancer #SABCS23 #oncology

Honoured of presenting the first safety analysis of the GIM26 - TRASTHER study at the oral communication session of #AIOM23 congress. Key topics: real world evidence, post-neoadjuvant T-DM1, safety data @UniGenova @GIM @AIOMtweet

We are so glad to share our immuno-genomic model for HR+/HER2- eBC based on the integrated evaluation of Recurrence Score & TILs. 💡Just out on European Journal of Cancer @vitti10 doi.org/10.1016/j.ejca…

SNPs of aromatase could be useful e biomarkers to personalize both extended andjuvant endocrine treatment and survivorship intervention in patients with ER+ early #breastcancer . Validation needed! ⬇️⬇️⬇️⬇️⬇️

Happy to share at #ESMO23 our work (2239P) on gene signatures capturing tertiary lymphoid structures (TLS) from pts prescreened at @SOLTI ACROPOLI trial ➡️ 14-gene B-cell signature IGG strongly associated with TLS across cancer types! @prat_aleix @TomasPascualMD @hospitalclinic

Si è concluso il 19th Meet The Professor | Advanced International Breast Cancer Course (AIBCC). Un ringraziamento speciale va ai Resp. Scientifici Pierfranco Conte, Valentina Guarneri, Philip Poortmans e @prat_aleix Prat e ai membri del Comitato Scientifico Internazionale.

Impact of the endocrine resistance/sensitivity classification according to consensus guidelines for advanced #BreastCancer Findings provide evidence on prognostic and clinical impact of the currently adopted classification in HR+/HER2− advanced BC bit.ly/3MQVul5

Outstanding @fara_bm at #ESMOBreast23 on HER2/ERBB2 mRNA leves and response to HER3-DXd in @_SOLTI TOTHER3 trial Lower ERBB2 👉better response from HER3-DXd Biological explanation still unknown. Maybe the answer is the HER2-HER3 dimerization affecting HER3 stability?

Jee Hyun Kim at #ESMOBreast23 on biomarker-driven strategies in HER2+ BC. Genomic biomarkers predict prognosis beyond clinical factors. Assays integrating both like #HER2DX can better guide tx. More evidence available at the poster display tomorrow at 12.15 @RevealGenomics

Great talk by @prat_aleix on HR+/HER2 BC biomarkers. My fav part: basal-like and immunogenic phenotypes can be found in HR+/HER2- too (even in ER>10%!), and are associated with 👎response to endocrine tp and 👍 response to chemo (and maybe IO) #ESMOBreast23

In case you missed it! 👉Landmark #POSITIVE study published in @NEJM by Dr. Ann Partridge and colleagues which helps us understand the impact of Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. #breastcancer #bcsm #pregnancy pubmed.ncbi.nlm.nih.gov/37133584/

HER2: bersaglio mobile? tinyurl.com/2kjksw4n

One of the most thought provoking and brilliant works in the HER2-low space. 👉most patients with HER2-neg MBC simultaneously harbor both HER2-0 and HER2-low lesions, even within the same organ. Congrats Tatjana Geukens & colleagues for the publication! ejcancer.com/article/S0959-…

I DUBBI DI MARTA | Podcast Le risposte della BCA alle domande delle pazienti 🔗tinyurl.com/4m5xj26t 🔊 24 - Cos'è l'immunoterapia e quando si usa nel tumore della mammella? Risponde @AlessiaRognone #breastcancer #Immunotherapy open.spotify.com/episode/7K2bOv…

On-line nuovi materiali! 📚Confronto del valore prognostico e predittivo dell’espressione genica immuno relata vs infiltrato linfocitario tumorale nel ca. mammario HER2+ in stadio precoce - A cura di Z. Ballatore (AN) tinyurl.com/2nsrysex jamanetwork.com/journals/jamao… @JAMAOnc